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Editorial on the Research Topic
Early Origins of Psoriatic Arthritis
Psoriasis (PSO) is a chronic inflammatory skin disease affecting 1–3% of the general population.
An estimate of 10–30% of PSO patients develop psoriatic arthritis (PsA) with arthritis, dactylitis,
enthesitis, and axial involvement during their lifetime. PsA is associated with structural damage,
reduced quality of life, disability, and mortality (1). Clinically apparent PsA is often associated
with systemic inflammation, structural damage of the joints may be noted, and eventually resulting
in physical functioning limitation. Thus, early detection of PsA can lead to better outcomes and
prevent irreversible damage. A deeper understanding of the early phase of the disease is important
to achieve better outcomes, avert damage, and allow better, and more detailed risk stratification
of PSO patients at-risk for disease progression. It is known that particular clinical [for example,
presence of nail involvement of PSO patients (2)], serological [e.g., CXCL10 (3)], or imaging factors
[subclinical inflammation and osteoproliferative changes at entheseal areas (4, 5)] have a good
prognostic value. Despite these important findings, further knowledge about the early phase of
PsA and the in-depth characterization of patients at-risk for developing PsA is needed. Basically,
the example of the PSO-PsA continuum illustrates the importance of new concepts, especially
molecular classification concepts, to fully capture different aspects of inflammation in psoriatic
disease (6).
In our Research Topic, several reviews (Bolt et al.; Pennington and FitzGerald) emphasized the
importance of a comprehensive and valid biomarker assessment and a longitudinal characterization
of large cohorts of PSO patients at increased risk for PsA transition. As a prerequisite to achieving
a better understanding, it was emphasized that close collaboration between rheumatologists and
dermatologists is the basis for successful research and patient care. Various genetic, epigenetic,
cellular, and tissue markers, as well as clinical and imaging markers, alone or in combination, could
serve as reliable prognostic tools for assessing the risk of developing PsA (Bolt et al.; Pennington
and FitzGerald). These reviews showed that the research field is currently undergoing a rapid and
successful development, with ever new findings and generation of important data.
As Pennington and Fitzgerald noted, prospective studies could validate the biomarker-based
prognostic model in early and established disease stages, particularly to validate proteins that can
distinguish PsA from PSO, to determine negative and positive predictive values, clinical utility,
and cost-effectiveness (Pennington and FitzGerald). In addition, Bolt et al. have explicitly pointed
out that prospective study designs should particularly focus on obtaining, in addition to liquid
biopsies, serial tissue samples of skin, synovium, or entheseal tissue to reveal which molecular and
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cellular processes change during the transition from PSO to PsA.
Many efforts are being undertaken in this field, particularly in
clinical research, to unravel the precise immunopathogenesis of
PsA. Fortunately, prospective clinical trials are currently being
undertaken in this area, for example, on entheseal biopsies
(EudraCT 2018-004734-15). Together with animal models that
mimic this transition, these studies will contribute to a better
understanding of PsA development and ultimately will lead to
the development of treatments that prevent the onset of PsA.
Ultimately, the mid-term goal is to design stratified clinical trials
for primary PsA prevention and to test and make available to our
patients a targeted and patient-centered therapy.
What we further learned from our Research Topic is that
the use of digital health technologies (eHealth) could help
to provide early and reliable disease prognosis and diagnosis
while conserving health resources (Fagni et al.). Various
eHealth solutions such as telemedicine, mobile technologies,
and in particular symptom checkers, could be helpful in
this regard. Telemedicine enables remote rheumatology visits
and consultations, while mobile technologies can improve
monitoring by allowing patients to continuously self-report
symptoms and disease-related parameters. Symptom checkers
have the potential to refer patients to a physician earlier
in their disease, minimizing diagnostic delays. Overall, these
interventions could lead to earlier diagnosis of arthritis,
improved monitoring, and better control of the disease while
increasing the capacity of referral centers. The review (Fagni
et al.) emphasizes the great potential of these strategies, but
also states that to date, promising results have been observed
primarily in rheumatoid arthritis and less so in psoriatic
disease. Therefore, until validated tools for PsA are developed
and tested in clinical trials, the potential of eHealth in this
area remains partly speculative. If successful, these new digital
approaches could address diagnostic delays and low adherence,
improve disease surveillance, and ultimately lead to better
disease outcomes.
In the original paper presented in this Research Topic,
Zabotti et al. demonstrated that it is worthwhile to distinguish
between peripheral and axial forms of spondyloarthropathy,
especially with regard to treatment patterns and clinical
characteristics. It was shown that (i) peripheral SpA patients
had significantly more skin and nail PSO than axial ones and
(ii) that most axial SpA patients (77%) started a biological
therapy while over half of peripheral patients started with
conventional disease-modifying antirheumatic drugs. These data
are important because they show once again that psoriatic
disease plays an important role for the entire spectrum
of spondyloarthropathies.
In summary, our Resarch Topic demonstrated that the field of
early diagnosis of PsA is undergoing dramatic change, intensive
research with productive results is emerging, and there is
therefore reasonable hope that in the future a greater proportion
of PSO patients will be prevented from transition to PsA. In the
coming years, due to the concentrated global research efforts, for
example in the Innovative Medicines Initiative HIPPOCRATES,
important research results are expected and will contribute to
enable patient care based on precision medicine.
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